Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

The Thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis

(2011) Fu-Sheng Chou et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

How I treat acute myeloid leukemia

(2010) J. M. Rowe et al.   BLOOD

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

(2010) S. Miyawaki et al.   BLOOD

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

(2010) A. Kellum et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers

(2010) Gemma Matthys et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

(2010) Celine Callens et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag

(2010) Connie L. Erickson-Miller et al.   LEUKEMIA RESEARCH

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome

(2010) Irene Mavroudi et al.   LEUKEMIA RESEARCH

A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells

(2009) A. Kalota et al.   BLOOD

Differentiation therapy of leukemia: 3 decades of development

(2009) D. Nowak et al.   BLOOD

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

(2009) B. Will et al.   BLOOD

The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II  in Breast Cancer Cells

(2009) V. A. Rao et al.   CANCER RESEARCH

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies

(2009) Daphne D. Williams et al.   CLINICAL THERAPEUTICS

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

(2008) Connie L. Erickson-Miller et al.   STEM CELLS